1. Home
  2. BEAM vs BILL Comparison

BEAM vs BILL Comparison

Compare BEAM & BILL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$25.19

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

HOLD

Current Price

$43.61

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
BILL
Founded
2017
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.2B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
BEAM
BILL
Price
$25.19
$43.61
Analyst Decision
Buy
Buy
Analyst Count
12
21
Target Price
$50.75
$57.90
AVG Volume (30 Days)
2.6M
2.4M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
82.31
74.07
EPS
N/A
0.07
Revenue
$24,000.00
$1,462,570,000.00
Revenue This Year
N/A
$14.18
Revenue Next Year
$33.77
$13.83
P/E Ratio
N/A
$589.43
Revenue Growth
33.33
13.36
52 Week Low
$15.60
$31.41
52 Week High
$38.26
$57.21

Technical Indicators

Market Signals
Indicator
BEAM
BILL
Relative Strength Index (RSI) 30.23 60.90
Support Level $24.80 $42.06
Resistance Level $33.32 $46.70
Average True Range (ATR) 1.99 1.86
MACD -0.94 -0.01
Stochastic Oscillator 1.83 67.97

Price Performance

Historical Comparison
BEAM
BILL

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

Share on Social Networks: